Drug intelligence / Profile preview

FLQ-103

Development stage: Preclinical
Lead developer: FELIQS
Modality: Small Molecules
Administration: Ophthalmic

Overview

FLQ-103 is an investigational small molecule therapeutic being developed by FELIQS for the treatment of pterygium. Formulated as an eye drop for topical ophthalmic administration, FLQ-103 is designed to target oxidized lipids and inhibit lipid peroxidation and ferroptosis, which are implicated in the pathogenesis of ocular surface and retinal diseases. The drug is currently in preclinical development, progressing through IND-enabling studies.

Targets

Oxidized lipids / lipid peroxidation products

Beyond the preview

Go deeper on FLQ-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLQ-103.

Explore the full profile